D91B9BZ
Brachytherapy Larynx to None with Palladium 103 (Pd-103), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 9 Ear, Nose, Mouth and Throat |
| Operation | 1 Brachytherapy |
| Body Part | B Larynx |
| Approach | 9 High Dose Rate (HDR) |
| Device | B Palladium 103 (Pd-103) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.
The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.
Anatomy & Axis Detail
Larynx
The larynx houses the vocal folds and the cartilaginous framework responsible for voice production, airway protection during swallowing, and respiration, making it a site where treatment decisions weigh oncologic control heavily against preservation of voice and airway function. Brachytherapy of the larynx is far less common than external beam approaches, typically reserved for recurrent or residual disease after prior radiation, and requires placement of interstitial catheters directly into laryngeal tissue, often under direct laryngoscopic guidance given the compact, cartilage-bound anatomy and proximity to the airway. The confined space and risk of airway compromise or cartilage necrosis demand careful source positioning, and records should capture the specific laryngeal subsite treated, such as the glottis or supraglottis, along with the number of catheters placed.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Palladium 103 (Pd-103)
Palladium-103 is another low-dose-rate isotope used in permanent interstitial seed implants, chiefly for prostate brachytherapy, but its shorter half-life (about 17 days) delivers its therapeutic dose faster than I-125. Clinicians may favor it for higher-grade or faster-growing tumors where a more concentrated early dose is desired, while I-125 remains preferred for lower-risk, slower disease.
Coding & Documentation
Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.